ProCE Banner Activity

CENTAURUS: Final Analysis of Phase II Study With Daratumumab Monotherapy in Intermediate- or High-Risk Smoldering MM

Conference Coverage

With a median follow-up of approximately 7 years, daratumumab monotherapy continues to show clinical activity and manageable safety in patients with intermediate- or high-risk smoldering multiple myeloma.

Released: December 11, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.